Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection

A technology of ganoderma acid and dihydroxyl, which is applied to ganoderma acid 7,9(11),24-triene-3-one 15,26-dihydroxy-sterane triterpene in the preparation of drugs for preventing and/or treating EV71 infection In the field of application, it can solve the problems of the prevention and treatment of enterovirus 71 that have not been mentioned and applied, and achieve the effects of safe and effective toxic and side effects, improving the quality of treatment, and improving tolerance

Inactive Publication Date: 2012-07-04
WUHAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although ganoderma acid has been reported in anti-liver damage, the anti-viral effect on coxsackie virus has not been reported before, and the prevention and treatment of enterovirus 71 (EV71), which is more popular and highly pathogenic, The therapeutic effect has not yet been mentioned and applied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection
  • Application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy-sterane triterpene in preparation of medicament for preventing and/or treating EV71 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Detection test of the toxicity of ganoderic acid Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy on host cells (MTT method)

[0025] After culturing RD cells for 24-48 hours, when the RD cells are almost full of monolayer, the culture medium is discarded, trypsinization is added, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell incubator and culture for 18-24 hours to make the cells grow into a single layer for later use. Dilute the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy storage solution with the cell culture solution to form five concentration gradients, and then add different concentrations of drugs and discard them. In the cell culture wells of the clear liquid, 100μl per well, 3 holes for each concentration, and cell control wells (no drug is added, only the culture medium is added), and then 100μl cell culture medium is added to each well, and the cells are kept at 37°C. In the incubator, after 48 hours o...

Embodiment 2

[0029] Example 2: Determination of EV71's half-cell infection (TCID50)

[0030] The RD cells cultured as a monolayer are transferred to a 96-well cell culture plate, and placed in a cell incubator for 18-24 hours. The virus solution was serially diluted 10 times with the maintenance solution (10 -1 …10 -8 ). Discard the culture solution of each well of RD cultured as a monolayer, wash each well with PBS 3 times, add 100μl of virus solution of different concentrations to each well, adsorb at 37°C for 1.5h, aspirate and discard the virus diluent, and add 100μl to each well Maintenance solution, 10 replicates for each concentration, set up normal cell control wells. Observe the cell pathology (CPE) of each hole daily for 3 consecutive days and record the CPE situation. Then calculate the virus titer by the following formula.

[0031] PD / [log(dilution bove 50%)-log(dilution below 50%)]=[(%next bove 50%)-50%] / [(%next above 50%)-(%next below 50%)]

[0032] The virus concentration used...

Embodiment 3

[0033] Example 3: Experiment on the antiviral effect of ganoderic acid Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy on EV71

[0034] 1) The preventive effect of ganoderic acid Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy on EV71 virus infection

[0035] After culturing for 24-48h, when the RD cells are almost full of monolayer, the culture medium is discarded, trypsinization is added, and transferred to a 96-well sterile cell culture plate, 100μl per well. Place it in a cell incubator and culture for 18-24 hours to make the cells grow into a single layer for later use. Dilute the drug with cell culture medium fold. After dilution, add different concentrations of drugs to the cell culture wells where the supernatant is discarded, 100μl per well, repeat 3 wells for each concentration, and set up cell control wells (no virus or drug, only culture medium) and Virus control well (no medicine, virus, culture medium). After the drug was incubated for 1 hour, the supernatant was di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy in preparation of medicaments for preventing and/or treating enterovirus 71 infection. The invention confirms that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good antiviral effect in in-vitro enterovirus 71 (EV 71) infection cell tests. Meanwhile, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxyhas certain killing effect on enterovirus 71 (EV 71), can prevent enterovirus 71 (EV 71) infection, has good treating effect on enterovirus 71 (EV 71) infected cells, has good inhibition effect on viral replication, and has more significant effect than a positive control medicament of ribavirin. In addition, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good inhibition effect on inflammation responses caused by enterovirus 71 (EV 71), which reveals that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has the prospect of being developed into anti-enterovirus 71 (EV 71) medicaments.

Description

technical field [0001] The invention relates to the field of antiviral drugs, and relates to ganoderma acid C 30 h 46 o 3 (Lanosta-7,9(11), 24-trien- 3-one 15,26-dihydroxy, namely 7,9(11), 24-trien-3-one 15,26-dihydroxysterane triterpene) The new application of the invention, specifically its application in the preparation of medicines for the treatment and / or prevention of enterovirus 71 (EV71) infection. Background technique [0002] Enterovirus 71 (human enterovirus 71, EV71) is a member of the Picornaviridae Enterovirus genus, which was first isolated in 1969 from fecal samples of infants with central nervous system diseases in California. Usually EV71 infection will cause hand, foot and mouth disease, which is mild and mostly self-limiting, which is difficult to distinguish from hand, foot and mouth disease caused by Coxsackie A16. In addition, EV71 can also cause aseptic meningitis, brainstem encephalitis, acute flaccid paralysis, acute cardiopulmonary dysfunction ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P31/14
Inventor 吴建国张文婧陶君彦邬开朗金晶朱应
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap